Other Clinical Trial - Study to Evaluate the Safety & Pharmacokinetics of

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03381664` - Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants	Phase 1
	Completed	`NCT02650479` - Study of the Effects of Intravenous Exenatide on Cardiac Repolarization	Phase 1

See also

Status

Clinical Trial

Phase

Completed

NCT03381664 - Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants

Phase 1

Completed

NCT02650479 - Study of the Effects of Intravenous Exenatide on Cardiac Repolarization

Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04341077
Study type	Interventional
Source	Jiangsu HengRui Medicine Co., Ltd.
Contact	Yuya Wang, Ph.D
Phone	+86-13918749176
Email	wangyuya@hrglobe.cn
Status	Not yet recruiting
Phase	Phase 1
Start date	April 10, 2020
Completion date	October 20, 2020

Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms